Abstract Body

Despite effective administration of combination antiretroviral therapy to HIV-1–infected pregnant women, mother-to-child transmission (MTCT) of HIV-1 remains a significant global public health concern. Co-pathogens that pose threats to the developing fetus include human cytomegalovirus (HCMV), may also facilitate in utero transmission of HIV-1 in populations where co-infection is common. HCMV infects up to 90% of reproductive-age women in developing and developed countries. We hypothesize that HCMV promotes in utero transmission through increased immune activation, local inflammation, and maternal stimulation of fetal/placental macrophages (or Hofbauer cells [HC]) to increase susceptibility to HIV-1. Strong associations between in utero HCMV infection and a higher incidence of MTCT of HIV-1 have been documented; however, the mechanisms that increase MTCT remain unknown.

With written informed consent, placentae/cord blood were collected from 15 HIV-1/Hep B/HCMV seronegative women (>18 years) at Emory Midtown Hospital in Atlanta, GA. In this study, myeloid subsets were exposed to HCMV in vitro, followed by HIV-1BaL. Cells were also treated with IFN-α/IFN-β. Viral replication was determined by HIV-1 p24 ELISA. qPCR, FACS, and Western blot analysis determined the expression of CCR5, activation markers, and antiviral ISGs. Cytokines and IFNs were measured by ELISA. Data were analyzed by using Student’s t-test and Mann-Whitney test.

HCMV exposure upregulated expression of the HIV-1 co-receptor CCR5, along with activation markers (CD16, CD80 and HLA-DR) on HCs. HCMV significantly induced the secretion of proinflammatory cytokines (IL-6 and TNF-α) by HCs, which enhanced their susceptibility to HIV-1 infection. We also showed type-I IFNs alone potently restrict HIV-1 replication in HCs, however HCMV infection inhibits Stat2 activation, which may override type-I IFN-induced protection to promote HIV-1 infection.

These data suggest that activation and local inflammation induced by maternal HCMV in utero alter CCR5 expression in macrophages at the feto-maternal interface to promote MTCT of HIV-1. We also present evidence that HCMV inhibits type-I IFN-dependent Stat2 signaling in the placenta, which may disrupt the intrinsic antiviral response in this compartment. Identifying biological determinants of MTCT provides a sentinel foundation upon which to design strategies for prenatal prophylaxis and the development of effective immunotherapies.